是否到了前列腺癌诊断中使用双参数磁共振成像的最佳时机？
Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?
机构信息
UCL Medical School, University College London, London, UK; BURST Research Collaborative, London, UK.
Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, Whipps Cross Hospital, Barts Health NHS Trust, London, UK.
出版信息
Eur Urol. 2022 Jul;82(1):1-2. doi: 10.1016/j.eururo.2022.02.021. Epub 2022 Mar 8.
The PRIME (PRostate Imaging using Mri +/- contrast Enhancement) study is evaluating whether quicker, cheaper, and less invasive biparametric magnetic resonance imaging (bpMRI) is noninferior to multiparametric MRI in diagnosing clinically significant prostate cancer (PCa). If the study results confirm that bpMRI is not inferior, it could become the new standard of care for PCa diagnosis and streamline the diagnosis pathway so that all men who need MRI have access to this diagnostic tool.
PRIME（使用 MRI +/- 对比增强的前列腺成像）研究正在评估更快、更便宜、侵入性更小的双参数磁共振成像（bpMRI）是否在诊断临床显著前列腺癌（PCa）方面不劣于多参数 MRI。如果研究结果证实 bpMRI 不劣于后者，它可能成为 PCa 诊断的新标准，并简化诊断途径，以便所有需要 MRI 的男性都能获得这种诊断工具。
Zotero 插件